PubMed:12626384 / 234-411 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T3","span":{"begin":0,"end":177},"obj":"Sentence"},{"id":"T3","span":{"begin":0,"end":177},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T7","span":{"begin":16,"end":23},"obj":"FMAID:67257"},{"id":"_T8","span":{"begin":16,"end":23},"obj":"FMAID:165447"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"uniprot-human","denotations":[{"id":"T2","span":{"begin":49,"end":59},"obj":"http://www.uniprot.org/uniprot/P06280"},{"id":"T3","span":{"begin":80,"end":90},"obj":"http://www.uniprot.org/uniprot/P06280"}],"text":"Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":60,"end":64},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/3554"},{"id":"T2","span":{"begin":60,"end":64},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/158455"}],"text":"Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"EDAM-topics","denotations":[{"id":"T6","span":{"begin":16,"end":23},"obj":"http://edamontology.org/topic_0078"},{"id":"T7","span":{"begin":169,"end":176},"obj":"http://edamontology.org/topic_0634"}],"text":"Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"EDAM-DFO","denotations":[{"id":"T2","span":{"begin":16,"end":23},"obj":"http://edamontology.org/format_1208"},{"id":"T3","span":{"begin":16,"end":23},"obj":"http://edamontology.org/data_1467"}],"text":"Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}

{"project":"mondo_disease","denotations":[{"id":"T4","span":{"begin":163,"end":176},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0010526"}],"text":"Two recombinant protein therapeutics, Fabrazyme (agalsidase beta) and Replagal (agalsidase alfa), have been approved in Europe as enzyme replacement therapies for Fabry disease."}